Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: 225 mg BNC210Drug: Placebo
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Bionomics Limited
- Target Recruit Count
- 332
- Registration Number
- NCT06510504
- Locations
- 🇺🇸
AFFIRM-1 Study Site, Austin, Texas, United States
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
- Conditions
- Social Anxiety Disorder
- Interventions
- Drug: 225 mg BNC210Drug: 675 mg BNC210Drug: Placebo
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Bionomics Limited
- Target Recruit Count
- 151
- Registration Number
- NCT05193409
- Locations
- 🇺🇸
PREVAIL Study Clinical Trial Site, Draper, Utah, United States
A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Bionomics Limited
- Target Recruit Count
- 212
- Registration Number
- NCT04951076
- Locations
- 🇬🇧
ATTUNE Study Clinical Trial Site, Stockton-on-Tees, United Kingdom
🇺🇸ATTTUNE Study Clinical Trial Site, Jacksonville, Florida, United States
A Study of BNC210 in Elderly Patients With Agitation
- First Posted Date
- 2018-06-07
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- Bionomics Limited
- Target Recruit Count
- 38
- Registration Number
- NCT03548194
- Locations
- 🇦🇺
Prince of Wales Hospital, Sydney, New South Wales, Australia
🇦🇺Modbury Hospital, Adelaide, South Australia, Australia
🇦🇺Northern Health, Melbourne, Victoria, Australia
Phase II Study of BNC210 in PTSD
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Bionomics Limited
- Target Recruit Count
- 193
- Registration Number
- NCT02933606
- Prev
- 1
- 2
- Next
News
Bionomics' BNC210 Shows Positive Phase 2 Results in PTSD Patients, Phase 3 Planned
Bionomics' BNC210 demonstrated statistically significant improvement in PTSD symptom severity compared to placebo at Week 12, with benefits observed as early as Week 4.
BNC210 Shows Promise in Phase IIb Trial for PTSD Treatment
A Phase IIb trial of BNC210, a novel α7 nicotinic acetylcholine receptor modulator, demonstrated significant improvement in PTSD symptom severity as early as 4 weeks.
Bionomics Advances BNC210 Phase 3 Trial for Social Anxiety Disorder and Strategic Partnership with Merck
Bionomics initiates Phase 3 trial for BNC210 in social anxiety disorder (SAD) after successful regulatory interactions and IP portfolio expansion, with data readout anticipated in Q3 2025.